Search clinical trials for: Residual Cancer

Total 87343 results

Shanghai Chest Hospital

Recruiting

A Study of Molecular Residual, Dynamic Monitoring and Recurrence of Stage III Driver Mutated NSCLC

Non Small Cell Lung Cancer

China
Sir Run Run Shaw Hospital

Not yet recruiting

A Study of SBRT Combined With Puterizumab in Intrapulmonary Metastasis From NSCLC

Non-Small-Cell Lung Cancer
Peter MacCallum Cancer Centre, Australia
AbbVie

Not yet recruiting

MRD-Directed Consolidation With Epcor-only or Epcor-R2 Post Anti-CD19 CAR TCell Therapy for Large B-Cell Lymphoma (EpLCART)

Relapsed/Refractory Large B-cell Lymphoma

Australia
Exact Sciences Corporation
NSABP Foundation Inc

Not yet recruiting

EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)

Breast Cancer
Exact Sciences Corporation
Labcorp Corporation of America Holdings, Inc

Recruiting

First CORRECT Study of Minimal Residual Disease (MRD) Detection in Colorectal Cancer (MRD)

Colorectal Cancer

United Kingdom, Spain, Italy, Israel
University College, London
University College London Hospitals

Recruiting

Study to Evaluate a New Method to Detect Residual Tumours During Surgery for Prostate Cancer Using Confocal Microscopy

Prostate Cancer

United Kingdom
AbbVie

Recruiting

A Study to Assess Frequency of Undetectable Minimal Residual Disease (uMRD) in Adult Participants With Chronic Lymphocytic Leukemia (CLL) Receiving Oral Venetoclax Tablets ± Intravenously (IV) Infused Rituximab in Routine Clinical Practice in Japan

Chronic Lymphocytic Leukemia

Japan
M.D. Anderson Cancer Center
Bellicum Pharmaceuticals, Inc.

Not yet recruiting

Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD)

Colorectal Cancer | Minimal Residual Disease

United States
Gustave Roussy, Cancer Campus, Grand Paris
BeiGene; C2i Genomics

Not yet recruiting

tislelizUMaB in canceR Patients With molEcuLar residuaL Disease (UMBRELLA)

Soft Tissue Sarcoma | Cancer | Lung Cancer | Pancreas Cancer | Colo-rectal Cancer

France
Fudan University

Not yet recruiting

Adjuvant Target Therapy Guided by ctDNA-MRD in Patients With EGFR-mutant II-IIIA Non-small Cell Lung Cancer (ECTOP-1022)

Lung Cancer | Minimal Residual Disease | EGFR Gene Mutation
University Health Network, Toronto

Recruiting

Clear Me: Interception Trial to Detect and Clear Molecular Residual Disease in Patients With High-risk Melanoma (ClearMe)

Cutaneous Melanoma | Mucosal Melanoma | Melanoma Stage IV

Canada
University Hospital, Montpellier

Not yet recruiting

French Assessment of MRD by Liquid Biopsies in Stage III CRC Patients (FRENCH.MRD.CRC)

Colorectal Cancer | Minimal Residual Disease | Liquid Biopsy | Stage III Colon Cancer
University Hospital, Montpellier

Not yet recruiting

French Assessment of MRD by Liquid Biopsies in Colorectal With Liver Metastasis Patients (FRENCH.MRD.CRLM)

Colorectal Cancer | Liver Metastases | Minimal Residual Disease | Liquid Biopsy | Stage IV Colorectal Cancer | ctDNA
University Hospital, Montpellier

Not yet recruiting

French Assessment of MRD by Liquid Biopsies in PDAC Patients (FRENCH.MRD.PDAC)

Pancreatic Ductal Adenocarcinoma | Pancreatic Cancer Resectable | Minimal Residual Disease | Liquid Biopsy | ctDNA
The First Hospital of Jilin University

Recruiting

Detection of Minimal Residual Disease in Resectable Stage II-IIIB Non-small Cell Lung Cancer

Lung Cancer

China
Henan Cancer Hospital

Recruiting

The Maintenance Treatment of "ITIVA" in AML Patients

Acute Myeloid Leukemia | Thalidomide | Maintenance Treatment | Minor Residue Disease | Interferon-α-1b | Interleukin-2 | Venentoclax | Azacitidine

China
Gruppo Oncologico del Nord-Ovest

Not yet recruiting

Adjuvant TRastuzumab Deruxtecan for HER2-positive Gastroesophageal Cancer With Persistence of miNImal Residual Disease (TRINITY)

Gastric Cancer | HER2-positive Gastric Cancer

Italy
The First Hospital of Jilin University

Recruiting

Effect of ICCAUT Strategy on Postoperative Urinary Dysfunction After Radical Rectal Cancer Surgery (ICCAUT-1)

Rectal Cancer | Urinary Dysfunction | Urinary Retention Postoperative | Urinary Catheterization

China
Personalis Inc.

Recruiting

ctDNA Based MRD Testing for NAC Monitoring in TNBC (B-STRONGER-I)

Minimal Residual Disease | TNBC - Triple-Negative Breast Cancer

United States
Mahidol University

Recruiting

Incidence of Residual Neuromuscular Blockade in Fraility in OncoGynae Surgery (FIGO)

Gynecologic Cancer | Frailty | General Anesthetic Drug Adverse Reaction | Neuromuscular Blockade | Surgical Complication

Thailand
Jiangsu Cancer Institute & Hospital

Recruiting

MRD-guided Prognosis Prediction and Adjuvant Treatment Based on CTC and ctDNA in NSCLC

Non-small Cell Lung Cancer

China
Qilu Hospital of Shandong University
The Affiliated Hospital of Qingdao University; Shandong Provincial Hospital; Jinan... and other collaborators

Recruiting

Minimal Residual Disease-guided Adjuvant Therapy for Gastric Cancer

Stage II-III Gastric Cancer

China
Fudan University
Shanghai Weihe Medical Laboratory Co., Ltd.

Not yet recruiting

Assessment of Early Pancreatic Cancer Prognosis by Minimal Residual Disease Using Multi-omics Approach

Pancreatic Ductal Adenocarcinoma

China
H. Lee Moffitt Cancer Center and Research Institute
Kite, A Gilead Company

Recruiting

Study of KTE-X19 in Minimal Residual Disease (MRD) Positive B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Acute Lymphoblastic Leukemia | B-Cell Lymphoblastic Leukemia

United States
Dartmouth-Hitchcock Medical Center

Not yet recruiting

A Study of Tetrathiomolybdate (TM) Plus Capecitabine

Triple Negative Breast Cancer | Residual Disease
University of Oklahoma

Not yet recruiting

Relugolix + Enzalutamide Study in High-Risk Prostate Cancer

Androgen Deprivation Therapy | Locally Advanced Prostate Cancer

United States
University Medical Center Groningen
Centre Hospitalier Universitaire de Nice; LungenClinic Grosshansdorf

Recruiting

Clinical Validation and Benchmarking of Top Performing ctDNA Diagnostics - Stage III NSCLC (MRD-LUNG)

Lung Cancer Stage III

France, Germany, Netherlands
Claus Lindbjerg Andersen
Karolinska Institutet; Medical University of Graz; University of Aarhus; Universitätsklinikum... and other collaborators

Recruiting

Clinical Validation and Benchmarking of Top Performing ctDNA Diagnostics - Colorectal Cancer

Colorectal Cancer Stage III | Liver Metastasis Colon Cancer

Germany, Denmark, Austria, France, Sweden
University of Maryland, Baltimore

Recruiting

Selective Adjuvant Therapy for HPV-mediated Oropharynx SCCs Based on Residual Circulating Tumor DNA Levels (SAVAL) (SAVAL)

Head and Neck Cancer | Head and Neck Squamous Cell Carcinoma | Oropharynx Cancer | HPV Positive Oropharyngeal Squamous Cell Carcinoma | Oropharynx Squamous Cell Carcinoma

United States
M.D. Anderson Cancer Center

Recruiting

Phase II Investigation of Pembrolizumab in Combination With Bevacizumab and Oral Cyclophosphamide in Patients With High Grade Ovarian Cancer and Surgically Documented Minimal Residual Disease After Frontline Therapy

Ovarian Cancer

United States
University of Aarhus
Aarhus University Hospital

Recruiting

DANISH.MRD: Danish Assessment of Minimal Residual Disease by Liquid Biopsies (DANISH_MRD)

Colorectal Neoplasms | Colorectal Cancer | Colorectal Adenocarcinoma | Colorectal Cancer Stage II | Colorectal Cancer Stage III | Colorectal Cancer Stage I

Denmark
Invitae Corporation
National Cancer Center Hospital East

Recruiting

Multicenter Study of Circulating Tumor DNA in Patients With Pancreatic Cancer Using a Personalized Panel (ARTEMIS-PC)

Pancreatic Cancer

Japan
Fudan University

Recruiting

SRS for NSCLC With Oligo-residual Intracranial Disease After First-line 3rd Generation EGFR-TKI

Non-small Cell Lung Cancer | Brain Metastases

China
WeiWei Xiao
Haplox Biotechnology Co., Ltd.

Recruiting

Predicting the Efficacy and Prognosis of Rectal Cancer Patients Based on ctDNA-MRD Technology

Minimal Residual Disease | Circulating Tumor DNA | Rectal Adenocarcinoma | Neoadjuvant Chemoradiotherapy

China
University of Southampton
AstraZeneca; Natera, Inc.

Recruiting

Developing ctDNA Guided Adjuvant Therapy for Gastrooesophageal Cancer (DECIPHER)

Gastrooesophageal Cancer

United Kingdom
Instituto do Cancer do Estado de São Paulo
Servier

Recruiting

Adult Acute Lymphoblastic Leukemia Treated With Pediatric Regimen in Brazil (BRALLA)

Acute Lymphoid Leukemia | Chemotherapeutic Toxicity | Minimal Residual Disease | Gene Abnormality

Brazil
Assistance Publique - Hôpitaux de Paris
CARPEM, Institut du Cancer Paris; Centre de recherche des Cordeliers; METHYS DX

Recruiting

Circulating Tumor DNA Study in Patients With Endometrial Cancer (ctDNA-endo)

Endometrial Cancer

France
Fondazione IRCCS Istituto Nazionale dei Tumori,...

Recruiting

Mini-invasive Detection of Residual Disease in Breast Cancer Patients in Remission After Primary Chemotherapy

Breast Cancer

Italy
Hebei Medical University Fourth Hospital

Recruiting

Minimally Residual of Esophageal Cancer 001 (ECMRD-001)

Esophageal Carcinoma | Minimal Residual Disease

China
Suzhou Municipal Hospital

Recruiting

Optimization of Postoperative Adjuvant Therapy for Cervical Cancer Based on MRD(Minimal Residual Disease)

Cervical Cancer

China
The First Hospital of Jilin University

Not yet recruiting

Minimal Residual Disease Dynamic Monitoring in First-Line Serplulimab Plus Chemotherapy in Treatment of Extensive Small Cell Lung Cancer: An Observational Study

Lung Cancer
Royal Marsden NHS Foundation Trust

Recruiting

The RESCUE Study: Survival and Functional Outcomes Following Salvage Surgery for RESidual or reCurrent sqUamous cEll Carcinoma of the Head and Neck (RESCUE)

Head and Neck Cancer

United Kingdom
Peking Union Medical College Hospital

Recruiting

The Value of Molecular Residual Disease Monitoring Based on ctDNA in Advanced or Metastatic Pancreatic Cancer (MAP-01)

Pancreatic Cancer | Metastatic Cancer | Advanced Cancer

China
Peking Union Medical College Hospital

Recruiting

The Value of Molecular Residual Disease Monitoring Based on ctDNA in Borderline Resectable or Locally Advanced Pancreatic Cancer (MAP-03)

Pancreatic Cancer | Locally Advanced

China
Peking Union Medical College Hospital

Recruiting

The Value of Molecular Residual Disease Monitoring Based on ctDNA in Resected Pancreatic Cancer (MAP-02)

Pancreatic Cancer | Resectable Carcinoma

China
Consorzio Oncotech
Roche Pharma AG

Recruiting

Observational Study of Effectiveness and Safety of Trastuzumab Emtansine (T-DM1) in HER2-positive Breast Cancer Patients With Residual Invasive Disease Following Neoadjuvant Chemotherapy and Anti-HER2 Target Therapy

Breast Cancer

Italy
Chongqing University Cancer Hospital

Recruiting

The Efficacy of Salvage Surgery in Patients With Residual Tumor After Concurrent Chemoradiation for Locally Advanced Cervical Cancer.

Cervical Cancer

China
The First Affiliated Hospital with Nanjing Medical...

Recruiting

ctDNA Detection of MRD in Predicting Postoperative Recurrence in Biliary Tract Cancers：A Multicenter Prospective Trial

Biliary Tract Cancer

China
Masonic Cancer Center, University of Minnesota

Recruiting

MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies

Acute Myeloid Leukemia | Juvenile Myelomonocytic Leukemia | Acute Lymphoblastic Leukemia | AML | Acute Leukemia | Neurofibromatosis 1 | Hematologic Malignancy | Myelodysplasia | Minimal Residual Disease | Chromosome Abnormality | Monosomy 7 | Remission | Somatic Mutation | Cytogenetic Abnormality | TP53 | Fetal Hemoglobin | Intrachromosomal Amplification of Chromosome... and other conditions

United States
Centre Jean Perrin
Groupement Inter-Régional de Recherche Clinique et d'Innovation Auvergne...

Recruiting

Prediction of Residual Disease by Circulating DNA Detection After Potentiated Radiotherapy for Locally Advanced Head and Neck Cancer (NeckTAR)

Locally Advanced Head and Neck Carcinoma

France

Search clinical trials for: Residual Cancer

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Trinidad & Tobago

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations